Laboratory-acquired infections and pathogen escapes worldwide between 2000 and 2021: a scoping review
- PMID: 38101440
- DOI: 10.1016/S2666-5247(23)00319-1
Laboratory-acquired infections and pathogen escapes worldwide between 2000 and 2021: a scoping review
Abstract
Laboratory-acquired infections (LAIs) and accidental pathogen escape from laboratory settings (APELS) are major concerns for the community. A risk-based approach for pathogen research management within a standard biosafety management framework is recommended but is challenging due to reasons such as inconsistency in risk tolerance and perception. Here, we performed a scoping review using publicly available, peer-reviewed journal and media reports of LAIs and instances of APELS between 2000 and 2021. We identified LAIs in 309 individuals in 94 reports for 51 pathogens. Eight fatalities (2·6% of all LAIs) were caused by infection with Neisseria meningitidis (n=3, 37·5%), Yersinia pestis (n=2, 25%), Salmonella enterica serotype Typhimurium (S Typhimurium; n=1, 12·5%), or Ebola virus (n=1, 12·5%) or were due to bovine spongiform encephalopathy (n=1, 12·5%). The top five LAI pathogens were S Typhimurium (n=154, 49·8%), Salmonella enteritidis (n=21, 6·8%), vaccinia virus (n=13, 4·2%), Brucella spp (n=12, 3·9%), and Brucella melitensis (n=11, 3·6%). 16 APELS were reported, including those for Bacillus anthracis, SARS-CoV, and poliovirus (n=3 each, 18·8%); Brucella spp and foot and mouth disease virus (n=2 each, 12·5%); and variola virus, Burkholderia pseudomallei, and influenza virus H5N1 (n=1 each, 6·3%). Continual improvement in LAI and APELS management via their root cause analysis and thorough investigation of such incidents is essential to prevent future occurrences. The results are biased due to the reliance on publicly available information, which emphasises the need for formalised global LAIs and APELS reporting to better understand the frequency of and circumstances surrounding these incidents.
Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of interests We declare no competing interests.
Similar articles
-
Laboratory-acquired infection in clinical laboratories and the incidence rate after Brucella exposure risk events: a systematic review and meta-analysis.J Hosp Infect. 2025 Jan;155:135-144. doi: 10.1016/j.jhin.2024.10.004. Epub 2024 Oct 18. J Hosp Infect. 2025. PMID: 39427772
-
A Review of Laboratory-Acquired Infections in the Asia-Pacific: Understanding Risk and the Need for Improved Biosafety for Veterinary and Zoonotic Diseases.Trop Med Infect Dis. 2018 Mar 26;3(2):36. doi: 10.3390/tropicalmed3020036. Trop Med Infect Dis. 2018. PMID: 30274433 Free PMC article. Review.
-
Improved Biosafety and Biosecurity Measures and/or Strategies to Tackle Laboratory-Acquired Infections and Related Risks.Int J Environ Res Public Health. 2018 Nov 29;15(12):2697. doi: 10.3390/ijerph15122697. Int J Environ Res Public Health. 2018. PMID: 30501091 Free PMC article. Review.
-
Epidemiology of Salmonella enterica serovars enteritidis and Typhimurium in animals and people in Scotland between 1990 and 2001.Vet Rec. 2003 Oct 25;153(17):517-20. doi: 10.1136/vr.153.17.517. Vet Rec. 2003. PMID: 14620550
-
Laboratory-acquired infections in Canada from 2016 to 2021.Can Commun Dis Rep. 2022 Jul 7;48(7-8):303-307. doi: 10.14745/ccdr.v48i78a02. eCollection 2022 Jul 7. Can Commun Dis Rep. 2022. PMID: 37334256 Free PMC article.
Cited by
-
Implementing governmental oversight of enhanced potential pandemic pathogen research.J Virol. 2024 Apr 16;98(4):e0023724. doi: 10.1128/jvi.00237-24. Epub 2024 Mar 13. J Virol. 2024. PMID: 38477586 Free PMC article. No abstract available.
-
Adipose-derived cells surpass muscle-derived cells in primary cell isolation efficacy.In Vitro Cell Dev Biol Anim. 2025 Jan;61(1):1-7. doi: 10.1007/s11626-024-00979-z. Epub 2024 Oct 8. In Vitro Cell Dev Biol Anim. 2025. PMID: 39379766 No abstract available.
-
A Review of Clinical Trials Involving Genetically Modified Bacteria, Bacteriophages and Their Associated Risk Assessments.Appl Biosaf. 2024 Dec 16;29(4):186-206. doi: 10.1089/apb.2024.0002. eCollection 2024 Dec. Appl Biosaf. 2024. PMID: 39735407 Free PMC article. Review.
-
A framework for biosafety assessment of microbial strains in Biotechnology applications.Bioinformation. 2025 May 31;21(5):1158-1162. doi: 10.6026/973206300211158. eCollection 2025. Bioinformation. 2025. PMID: 40822762 Free PMC article.
-
Grand (meta) challenges in planetary health: environmental, social, and cognitive.Front Public Health. 2024 Dec 5;12:1373787. doi: 10.3389/fpubh.2024.1373787. eCollection 2024. Front Public Health. 2024. PMID: 39703489 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous